However, the introduction of HER2-targeted mAb therapies including trastuzumab (Herceptin, Roche), pertuzumab (Perjeta, Roche), trastuzumab-emtansine (Kadcyla, Roche) and the HER2 tyrosine kinase inhibitors lapatinib (Tykerb, GlaxoSmithKline) and tucatinib (Tukysa, Cascadian Therapeutics) has improved the outcome of patients with HER2-positive BC (Swain et al. 2023). This evidence concerns the gene ERBB2 and breast cancer.